Compare Cassava Sciences Inc (FLNA) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Williams Companies Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 2245.7× Cassava Sciences Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Williams Companies Inc for 58 Days on average.
| FLNA | WMB | |
|---|---|---|
Market Cap | $39.40M | $88.48B |
Volume | 759,018 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $4.64 | $79.40 |
52-Week Low | $0.68 | $56.51 |
Typical Hold Time | 37 Days | 58 Days |
Enterprise Value | -$43.28M | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Williams Companies (WMB) trades at $71.46, down 1.28% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company benefits from stable fee-based revenues in the midstream energy sector, positioning it well for AI-driven natural gas demand growth.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus target, offering 22% upside potential. Key opportunities include dividend growth strategy and exposure to rising natural gas demand from data centers. Risks include energy market volatility, high debt levels at 52% debt-to-asset ratio, and execution challenges in capital-intensive projects. The stock's valuation at 28.47 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
